A Real-World Study of QL1706-Based Therapy for Solid Tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400093989

Enrollment

Unknown

Registered

2024-12-16

Start date

2024-12-20

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

Observation group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Subjects must meet all of the following enrollment criteria to be eligible for entry into this trial: 1. voluntary participation in this study by signing an informed consent form; 2. subjects with histologically or cytologically confirmed solid tumors; 3.The investigator determines that the subject is amenable to immunotherapy.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria are not eligible for enrollment: 1. women who are pregnant or breastfeeding; 2. other factors deemed by the investigator to be inappropriate for participation in the study.

Design outcomes

Primary

Measure	Time frame
Security;	—

Secondary

Measure	Time frame
Progression-free survival;Disease control rate;Overall survival;Objective response rate;	—

Countries

China

Contacts

Public ContactLei Yang

Nantong Cancer Hospital

leiyang.53@163.com+86 158 5139 8092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026